Payment overview · 2025
General Payments
$64.84
4 reported records · 4 companies
Healthcare provider profile · identity verified
Michael Miller, MD
Allopathic & Osteopathic Physicians|Family Medicine · FULTON, NY · NPI 1588045488
Verified facts
What the public records show
CMS Open Payments records show Michael Miller, MD received $64.84 in general payments during 2025 across 4 reported records.
SHIELD THERAPEUTICS INC accounted for 29.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $18.97 | 29.3% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $15.46 | 23.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.39 | 23.7% | 1 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $15.02 | 23.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $64.84 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $18.97 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $15.46 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $15.39 | 1 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $15.02 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
55 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 464 | 107 |
| Levothyroxine Sodium | Levothyroxine Sodium | 310 | 55 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 285 | 76 |
| Lisinopril | Lisinopril | 273 | 57 |
| Omeprazole | Omeprazole | 254 | 56 |
| Metformin Hcl | Metformin Hcl | 248 | 55 |
| Gabapentin | Gabapentin | 239 | 42 |
| Amlodipine Besylate | Amlodipine Besylate | 236 | 44 |
| Pantoprazole Sodium | Pantoprazole Sodium | 188 | 38 |
| Sertraline Hcl | Sertraline Hcl | 159 | 25 |
| Losartan Potassium | Losartan Potassium | 153 | 40 |
| Famotidine | Famotidine | 144 | 25 |
| Allopurinol | Allopurinol | 140 | 26 |
| Furosemide | Furosemide | 122 | 24 |
| Metoprolol Succinate | Metoprolol Succinate | 122 | 26 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 120 | 36 |
| Simvastatin | Simvastatin | 102 | 21 |
| Montelukast Sodium | Montelukast Sodium | 99 | 16 |
| Alendronate Sodium | Alendronate Sodium | 93 | 19 |
| Tamsulosin Hcl | Tamsulosin Hcl | 90 | 18 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 88 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 85 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 83 | 26 |
| Torsemide | Torsemide | 83 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 81 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 81 | 38 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 77 | 16 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 68 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 66 | 15 |
| Topiramate | Topiramate | 63 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 62 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 61 | 14 |
| Oxycodone Hcl | Oxycodone Hcl | 60 | 13 |
| Bupropion Xl | Bupropion Hcl | 56 | suppressed |
| Carvedilol | Carvedilol | 55 | 11 |
| Synthroid | Levothyroxine Sodium | 55 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 54 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 53 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 51 | 15 |
| Doxycycline Hyclate | Doxycycline Hyclate | 51 | 37 |
| Trazodone Hcl | Trazodone Hcl | 51 | 12 |
| Jardiance | Empagliflozin | 50 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 50 | 14 |
| Spironolactone | Spironolactone | 49 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 48 | 13 |
| Eliquis | Apixaban | 48 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 48 | 12 |
| Ozempic | Semaglutide | 48 | 20 |
| Prednisone | Prednisone | 48 | 29 |
| Alprazolam | Alprazolam | 47 | 18 |
| Atenolol | Atenolol | 47 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 47 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 47 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 46 | 14 |
| Trulicity | Dulaglutide | 45 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 44 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 42 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 38 | 13 |
| Baclofen | Baclofen | 38 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 38 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 37 | suppressed |
| Myrbetriq | Mirabegron | 36 | suppressed |
| Potassium Chloride | Potassium Chloride | 35 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 35 | 13 |
| Ondansetron Odt | Ondansetron | 34 | 14 |
| Fenofibrate | Fenofibrate Nanocrystallized | 32 | suppressed |
| Sucralfate | Sucralfate | 31 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 30 | suppressed |
| Risperidone | Risperidone | 29 | suppressed |
| Januvia | Sitagliptin Phosphate | 28 | suppressed |
| Tradjenta | Linagliptin | 28 | suppressed |
| Glipizide Er | Glipizide | 27 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 27 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 26 | 22 |
| Farxiga | Dapagliflozin Propanediol | 26 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 26 | suppressed |
| Ezetimibe | Ezetimibe | 25 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 25 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 25 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 24 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 24 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 23 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 23 | suppressed |
| Pentips Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 22 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 22 | suppressed |
| Pregabalin | Pregabalin | 22 | suppressed |
| Verapamil Sr | Verapamil Hcl | 22 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | 11 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 20 | suppressed |
| Fenofibrate | Fenofibrate | 20 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 20 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 18 | suppressed |
| Clotrimazole | Clotrimazole | 18 | suppressed |
| Glimepiride | Glimepiride | 18 | suppressed |
| Invokana | Canagliflozin | 18 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 18 | 11 |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 17 | suppressed |
| Ketoconazole | Ketoconazole | 17 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 17 | suppressed |
| Vascepa | Icosapent Ethyl | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Aripiprazole | Aripiprazole | 16 | suppressed |
| Azithromycin | Azithromycin | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 16 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 15 | suppressed |
| Diazepam | Diazepam | 15 | suppressed |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Nystatin | Nystatin | 15 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Meloxicam | Meloxicam | 14 | suppressed |
| Oxycontin | Oxycodone Hcl | 14 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 14 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 13 | suppressed |
| Celecoxib | Celecoxib | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 11 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 11 | suppressed |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Xyosted | Testosterone Enanthate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $64.84 · 4 records | SHIELD THERAPEUTICS INC | ACCRUFER, SHINGRIX, SUBLOCADE, VRAYLAR | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error